

9 July 2019

NZX Announcement

TRUSCREEN COMPLETES CAPITAL RAISING

Truscreen Limited (Truscreen or Company) (NZX: TRU) is pleased to advise that it has received firm commitments for the capital raising announced on 2 July 2019, raising NZ\$1,000,000, before costs.

The Company will issue 9,433,962 new ordinary shares at a price of 10.6 cents per share, an 18.5% discount to the last trading price on 1 July 2019. The New Shares will also be entitled to a free attaching option, exercisable at 13 cents per share with expiry date two years from date of issue. This raising includes placement shares (and attaching options) to be subscribed for by the Chairman in the amount of NZ\$106,000, which is subject to shareholder approval at the Annual Meeting of Shareholders to be held on 27 August 2019.

The funds will be used for working capital as the business grows to meet the expanding demand from those countries where the Company has established business, and for developing new markets identified for the Company's product.

For more information visit www.TruScreen.com or contact:

TruScreen

Martin Dillon

CEO

martindillon@truscreen.com

TruScreen

Guy Robertson

CFO

guyrobertson@truscreen.com

Investors

Investor Relations

Phone: +61 2 9237 2801

TruScreen@we-buchan.com

About TruScreen:

Watch our video on TruScreen: <http://truscreen.com/truscreen-the-company/truscreen-ultra-video/>

TruScreen is a Cervical Cancer Screening Device which offers the latest technology in cervical screening, providing real-time, accurate detection of pre-cancerous and cancerous cervical cells to help improve the health and well-being of women around the world. TruScreen's real-time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated proprietary algorithm framework is utilised to detect pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue.



TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing issues with Pap tests including failed samples, poor patient follow up, patient discomfort and the need for supporting laboratory infrastructures. As such, TruScreen target market is developing countries where no large scale cervical cancer screening programs and infrastructure are in place, such as; China, Mexico, Africa, Russia and India. TruScreen's cervical cancer screening device is EC certified for use throughout Europe and CFDA approved for sale in China. Truscreen gained recognition from Global NGO's WHO and Unitaid in a joint Cervical Cancer Technology Landscape released at the 72nd World Health Assembly.

For more information, visit our website at www.truscreen.com